Baricitinib Improves Bone Properties and Biomechanics in Patients with Rheumatoid Arthritis – Results of the Prospective Interventional BARE BONE Trial
Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print
The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.
These results come from the BARE-BONE trial, which is a prospective, single-arm, open-label, single-centre phase 4 study. Bone properties and synovial inflammation were assessed using CT scans and MRI at baseline, Week 24 and Week 52.
Keywords:
